SPK Acquisition Corp (SPK) Financial Statements (2024 and earlier)
Company Profile
Business Address |
ROOM 368, 302 BUWEI SHANGHAI, 200131 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
9/30/2022 MRQ | 12/31/2021 | |||
---|---|---|---|---|
ASSETS | ||||
Current Assets | ||||
Cash, cash equivalents, and short-term investments | 50,914 | |||
Short-term investments | 50,914 | |||
Other undisclosed current assets | 367 | |||
Total current assets: | 51,281 | |||
Noncurrent Assets | ||||
TOTAL ASSETS: | 51,281 | |||
LIABILITIES AND EQUITY | ||||
Liabilities | ||||
Current Liabilities | ||||
Accounts payable and accrued liabilities | 103 | |||
Accounts payable | 103 | |||
Due to related parties | 3 | |||
Other undisclosed current liabilities | 1,548 | |||
Total current liabilities: | 1,654 | |||
Noncurrent Liabilities | ||||
Total liabilities: | 1,654 | |||
Temporary equity, carrying amount | 136 | |||
Equity | ||||
Equity, attributable to parent | (1,285) | |||
Common stock | 0 | |||
Accumulated deficit | (1,285) | |||
Other undisclosed equity | 50,776 | |||
Total equity: | 49,491 | |||
TOTAL LIABILITIES AND EQUITY: | 51,281 |
Income Statement (P&L) ($ in thousands)
9/30/2022 TTM | 12/31/2021 | ||
---|---|---|---|
Revenues | 1,021 | ||
Underwriting income | ✕ | 1,018 | |
Gross profit: | 1,021 | ||
Operating expenses | (423) | ||
Operating income: | 599 | ||
Income from continuing operations: | 599 | ||
Income before gain (loss) on sale of properties: | ✕ | 176 | |
Loss from discontinued operations | (423) | ||
Other undisclosed net loss | (597) | ||
Net loss attributable to parent: | (421) | ||
Other undisclosed net income available to common stockholders, basic | 842 | ||
Net income available to common stockholders, basic: | 421 | ||
Other undisclosed net loss available to common stockholders, diluted | (842) | ||
Net loss available to common stockholders, diluted: | (421) |
Comprehensive Income ($ in thousands)
9/30/2022 TTM | 12/31/2021 | ||
---|---|---|---|
Net loss: | (421) | ||
Comprehensive loss, net of tax, attributable to parent: | (421) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.